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Abstract
Heterotopic ossification (HO) is the process by which calcified bone develops in soft
tissues. Because of the abnormal calcification, complications such as bone deformation,
loss of range of motion, and joint immobility adversely affect patients. There are many
genetic types of heterotopic ossification, namely fibrodysplasia ossificans progressiva,
progressive osseous heteroplasia, and Albright hereditary osteodystrophy. However, this
condition can also arise from surgery, burns, or traumatic injuries, so it is seen as an
important area for research in the future. There are various treatments available such as
non-steroidal anti-inflammatory drugs and radiation therapy, as well as combinations of
the two. The molecular basis of HO is currently being explored in hopes of developing
drugs that prevent the development of heterotopic bone. Additionally, new methods of
treatment that offer fewer side effects may be promising for patients in the future.
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Heterotopic Ossification: Cellular Basis, Symptoms, and Treatment

Background
Heterotopic ossification (HO) is the process by which bone calcifies in soft tissues
where it does not belong. In contrast to orthotopic ossification, which is the formation of
tissue in the correct anatomical positions, HO causes bone to grow between muscle
planes, eventually leading to some form of physical debilitation for patients (Mania et al.,
2009). Because heterotopic bone can form on muscles, ligaments, and tendons, there are
many different complications that can arise from its presence, depending on the location
of the body. This process of bone formation can arise in different ways, including
genetics, traumatic injury, and surgery.
Heterotopic ossification was first reported in literature in 1692 by Patin as
myositis ossificans progressiva syndrome, but there were similar reports given later on
from different cases. There were records of HO occurring from neurological injuries and
traumas, and in paraplegic patients. Although various types of heterotopic ossification
have been recognized and treatments have been utilized for years, there is still not a
complete understanding of this condition. A fully successful prevention of heterotopic
bone is still of interest to researchers, as this problem affects the lifestyle of those who
have it (Baird & Kang, 2009).
As a result of the unclear differentiation between the naturally occurring
ossification process and the heterotopic calcification, researchers and physicians find it
hard to investigate what actually causes the buildup of bone to occur. Since there are
multiple factors that are contributing to this process, especially on a molecular basis, the
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challenge of preventing this condition will continue to exist for years to come. However,
society now has access to the latest advances in technology that were not available when
HO was first reported. Advancement has come through imaging techniques and medical
technology, such as being able to prepare tissue samples for analysis. Because heterotopic
bone may interact with proximal tissues, it is important to identify differences in
composition. The configuration of the periosteum, a membrane that lines the outermost
surface of bone, is not affected by the development of new bone, although the existing
skeletal structure can be covered with more calcified bone (Baird & Kang, 2009).
Types of HO
Since heterotopic ossification is the process by which bone tissue develops
outside of the skeleton, it is common for HO to occur in the vicinity of joints. Overall, it
decreases range of motion and can cause complete joint ankylosis in which surgical
intervention is required. Usually, the development of HO occurs through one of three
routes: genetic predisposition, post-traumatic injury, or post-surgery. Most cases of HO
come from the two latter categories, so studies focused on preventing HO is especially
important for the medical field.
HO may be classified in a rare hereditary form or a most common acquired form,
due to injuries or joint replacements. To this day, there are three distinct genetic
hereditary forms known to humans: fibrodysplasia ossificans progressiva, progressive
osseous heteroplasia, and Albright hereditary osteodystrophy. When it is acquired, HO
occurs frequently after neurologic injuries including spinal trauma or a head injury. In
addition, it can occur in areas of the body where a joint is replaced, such as the hip,
shoulder, or elbow.
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Heterotopic ossification is often classified by its anatomic position or by the
effects seen with the patient’s range of motion (ROM). In the case of traumatic injuries,
Hastings and Graham have developed a classification of HO based on range of motion.
The first group, Class I, includes patients that are known to have HO, but do not present
any difficulties with ROM, making the heterotopic bone less clinically relevant. Class II
HO patients tend to have limitations with ROM, such as lack of full extension and/or
flexion of the elbow. Also, there may be problems associated with pronation and
supination along with the flexion and extension. Depending on which plane of motion is
involved, Class II HO can be divided into three further subcategories. The last type, Class
III HO, includes patients that have ankylosis (joint stiffness) in addition to the problems
with flexion/extension and pronation/supination (Casavant & Hastings, 2006).
Genetic case: fibrodysplasia ossificans progressiva (FOP). In this genetic
disorder, heterotopic ossification begins at an early age and progressively develops at
multiple periarticular sites. Because of the extensive progression, it eventually causes the
patient to be completely immobilized. This condition is very rare, as it is estimated to
affect only about 400 patients in the United States. It is thought to occur by random
mutations and there has been no linkage to gender, race, or ethnic group. However, there
have been reported cases of autosomal dominant familial transmission, suggesting that it
may not occur primarily though random mutations. Its primary classification may not be
identified with familial transmission because those with FOP have a weakened ability to
reproduce.
FOP develops in patients at a young age, initially identified though lesions on the
back, as soft masses are present on the upper back and shoulder girdle (Cohen et al.,
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1993). Due to the nature of the disorder, more lesions develop as the patient ages, moving
from the axial skeleton to the appendicular skeleton. The axial skeleton consists of the
bones that lie along the central axis of the human body, including the skull, ribcage,
sternum, and vertebral column. On the other hand, the appendicular skeleton contains
bones that are involved in movement, including the upper and lower limbs (Chen, Yang,
Chuang, Huang, & Yang, 2009).

Figure 1: In FOP, ossification begins with the axial skeleton and moves to the
appendicular skeleton. This x-ray picture shows ossification of the posterior muscles of
the cervical spine (McCarthy, 611).

Therefore, patients are more prone to developing a severe scoliosis, or curving of
the spinal cord. As predicted, this causes a severe problem with movement, leading most
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patients to be crippled by age thirty. Various skeletal abnormalities develop such as
shortened thumbs and toes, and short and wide femoral necks. It is these common
characteristics that help identify the disorder for physicians (Smith, Russell, & Woods,
1976). Most patients do not live to middle adulthood, eventually dying from pneumonia.
Genetic case: progressive osseous heteroplasia (POH). Progressive osseous
heteroplasia, POH, was identified in 1994 after a group of patients were thought to have
had fibrodysplasia ossificans progressiva (FOP). The new patients had a different bone
formation pattern than those of FOP, leading to the identification of a new disorder with a
different mutation. Rather than the extensive ossification identified in FOP, typical POH
presents with ossification of subcutaneous tissue and the skin. The early signs of POH
can be seen in infancy, where a maculopapular rash develops on the skin. This part of the
skin will eventually develop into future sites of intradermal ossification. Unlike FOP,
there is no malformation of the toes, and the ossification occurs within a membrane
(intramembranous) rather than the endochondral ossification identified with FOP (Kaplan
et al., 1994).
The genetic basis for POH is the inactivating mutation of the GNAS1 gene, which
codes for the alpha subunit of the activating G protein complex at chromosome 20 (Eddy
et al., 2000). A signaling protein, the G protein helps to transmit information from the
nucleus to the cell membrane and vice versa. The mutation of the G protein in POH also
causes Albright’s hereditary osteodystropy (AHO), which is another genetic disorder that
presents problems with ossification. Patients with AHO (formerly known as
pseudohypoparathyroidism) have a resistance to parathyroid hormone (PTH), resulting in
high levels of PTH, which then circulates throughout the body.

HETEROTOPIC OSSIFICATION

9

Major physical symptoms include soft tissue calcification, short stature, and
mental retardation. The mutation of the GNAS1 gene can cause both AHO and POH, but
researchers have been able to link the distinction to genetic imprinting. When the mutated
gene results from a male, it causes POH, while AHO results from a maternal gene
mutation (Weinstein, Chen, & Liu, 2002). While there has only been overexpression of
bone morphogenetic receptor (BMP) proteins in certain types of heterotopic ossification
from the mutation of the G protein, it may provide pathways to understanding how and
why calcification occurs in soft tissue.
Neurogenic heterotopic ossification. It is common for neurological lesions, or
neurological tissue damage to cause the development of heterotopic bone near joints
(Botte et al., 1997). For example, almost a quarter of spinal cord injury patients have
heterotopic bone forming near the spine, many times causing severe joint limitations.
Those with neurogenic HO have damage continuing to occur in larger joints, such as the
hip, knees, and elbows. Because those joints are vital to movement and everyday activity,
heterotopic bone can prevent patients from being able to walk or have any type of active
lifestyle. Heterotopic ossification can begin in the joint(s) two months after the
neurologic injury. Complete development of the osseous bone takes place within two
years of the injury, many times causing ankylosis of the affected joint. Ankylosis is
known to cause stiffening and immobility of a joint due to a disease, trauma, injury, or
abnormal bone fusion.
Ossification following surgery. One of the most common procedures done by
modern orthopaedic surgeons is a total hip arthroplasty, commonly known as a hip
replacement. Although this surgery assists patients with regaining an active lifestyle, it
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commonly causes about 60 to 90 % of patients to have heterotopic ossification. While the
majority of HO cases do not present symptoms and are clinically insignificant, there
exists a 1-2% of patients that are affected by the presence of heterotopic bone. However,
there are risk factors that can help predict and identify those that would be expected to
have HO. For example, the elbow is seen as an unforgivable joint, meaning that traumatic
injuries to the elbow usually result in some complication, even after treatment. However,
surgeons can take measures in order to reduce the potential for heterotopic bone growth
so that the amount of bone that does develop after surgery is of little clinical significance
(Kantor, Cummins, & Tanzer, 2005).
HO following burns. While most heterotopic ossification is rare, it is not
uncommon to be present after burns, occurring in about 1 to 3% of burn patients (Kolar
& Vrabec, 1959). For patients that have sustained thermal burns, the joint most affected
by HO is the elbow. The elbow tends to have limited movement after thermal burns,
leading to loss in ROM and/or ankylosis. It is speculated that the elbow is greatly affected
due to the compression of the ulnar nerve (Evans, 1991).
HO and traumatic injuries. Some causes of heterotopic ossification are related
to traumatic injuries. Due to the nature of certain injuries, areas of the body deal
differently with heterotopic development, as it is known to cause numerous complications
and varying levels of severity. The onset of heterotopic ossification can occur naturally,
or from a posttraumatic injury. It is commonly known that its occurrence is higher in
patients that undergo open reduction and internal fixation of a fracture. In particular, with
an elbow fracture, dislocation, or fracture-dislocation, the incidence of traumatic HO
approaches 90%. When HO develops in the elbow joint, it causes loss of range of motion
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(ROM), disabling the patient from having terminal extension and severely limiting
flexion. The observed loss in ROM is due to the inability of the muscles to contract while
the heterotopic bone exists and/or develops in the muscle plane.
For traumatic injuries, the most common place for HO to develop is at the joints
or within the spinal cord. Sports-related injuries that require surgery involving open
reduction and internal fixation can lead to HO. For example, injuries that occur at the
elbow, humerus, or hip are commonly linked to HO due to its location. The site of the
bone fracture helps determine the extent of the HO that develops (amount in size) and the
ability for the joint to continue working properly. If the injury site is proximal to a joint,
the precursors to osteoblasts are able to aggregate and form bone away from the
necessary location. A large majority of patients that have hip fractures develop HO, and
that percentage increases if hip replacement and/or open reduction and internal fixation
are performed. This parallels with similar occurrences in the upper and lower extremities.
Cellular/Genetic Basis
Prior research conducted by various institutions of health has shown how HO can
occur and the genetic basis, including gene expression. The exact biological mechanisms
of acquired HO formation are yet to be determined. However, studies have mainly
focused on two different approaches including the research of a humoral factor as an
inductive agent in neurogenic HO and the measure of the osteoblast activity in HOisolated cells. Advances in genetics have led to the identification of many genes involved
in the different steps of osteoblast differentiation. In recent years, there have been a
variety of powerful and sensitive methods to quantify mRNA expression.
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Structure and Bone Mineral Content
In the past, it was thought that heterotopic ossification occurred as a result of
cancellous bone, woven bone, or cortical bone. Additionally, the results from
radiographic assessments and light microscopy have given doubts about the bone
structure and mineral content, due to the lack of fine resolution. However, a recent study
was able to find a more accurate HO characterization. Using scanning electron
microscopy (SEM) and backscatter electron (BSE) imaging, researchers found that
heterotopic bone is composed a mixture of cortical and cancellous bone, along with
fibrocartilage. A case study demonstrated that mineralization levels were dependent on
the individual patients, with a great amount hypermineralization occurring among older
patients. Using BSE and histologic stains, researchers found that the composition of HO
was still changing, even though initial bone developed up to three years ago. It was
osteoclastic resorption and osteoid deposition that demonstrated this phenomenon.
Overall, BSE was able to provide an accurate understanding of HO bone mineralization
and structure. This insight may be able to improve surgical planning and change
treatment strategies for patients in the future (Isaacson, Brown, Brunker, Higgins, &
Bloebaum, 2011).
Genetic Basis for FOP
The classic phenotype of ossification suggested that the primary molecular
pathology involves the bone morphogenetic protein (BMP) signaling pathway. A number
of discoveries provided evidence of profound dysregulation of the BMP signaling
pathway in cells from patients who had FOP.
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In FOP, scientists have identified a linkage to 2q23–24.9, the gene that encodes
activin receptor IA (ACVR1). ACVR1 is a BMP type I receptor, so its DNA sequence
revealed that the same heterozygous missense mutation in the glycine–serine (GS)
activation domain (c.617G>A;R206H) occurs in all classically affected individuals
examined. Hypothetical protein structure models are being developed to understand both
inter-and intramolecular interactions of the mutant receptor. It is still unclear how the
R206H mutation in ACVR1/ALK2 is able to interfere with BMP signaling in FOP, but it
could involve dysregulation of BMP receptor oligomerization, internalization, and/or
degradation.
Other genetic studies suggest that FOP is due to overexpression of BMP4.
Although there has been no proven mutation in the gene for BMP4, researchers have
identified two possible genetic mutations associated with this disorder: mutations on
chromosome 4 (4Q 27–31), a region known to contain at least one locus involving the
BMP pathway, and mutation of the noggin gene. Noggin is one of several BMP4
antagonists. The gene for noggin is normally upregulated when BMP4 is secreted.
However, in FOP the upregulation of noggin is reduced, and this may result in unopposed
BMP stimulation (Kaplan et al., 2009).
Pathogenesis of HO
In order for heterotopic bone to form, there are four things that must happen.
First, there must be an inciting event, such as a trauma. Secondly, a signal from the site of
injury, most likely a protein secreted from the cells of the injured tissue or from
inflammatory cells arriving in response to the tissue injury, must be present. Third, a
supply of mesenchymal cells whose genetic machinery is not fully committed must be
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available for osteogenesis. When given the appropriate signal, genes that synthesize
osteoid and chondroid (matrix) are activated and cause mesenchymal cells to differentiate
into osteoblasts or chondroblasts. Lastly, there must be an environment where heterotopic
bone can continue to develop and thrive (McCarthy & Sundaram, 2005).
Symptoms
Symptoms of heterotopic ossification, including loss of range of motion (ROM),
the presence of heterotopic bone, and the impact that it has on areas of the body nonproximal to the site of injury will be examined.
A major topic on the discussion of heterotopic ossification is the impact that it has
on people and their normal physical activity. One of the major impacts that heterotopic
ossification has on patients is a significant change in the range of motion for patients.
ROM is the distance and direction that a joint can move between the flexed position and
the extended position. In the case of HO, it severely limits the ROM in patients, so that it
inhibits regular day-to-day activity. The reduced range of motion may be a mechanical
problem with the specific joint or injury, from diseases such as osteoarthritis, rheumatoid
arthritis, or bone fracture that requires open reduction and internal fixation. The ROM
lost in a joint can be determined using a goniometer, which measures (in degrees) how
well the joint can undergo flexion and extension. Often, it is used during physical therapy
to determine progress, as the ROM is measured before and after treatment. Sometimes,
the practice of physical and/or occupational therapy will not help increase ROM,
especially if therapy is not completed soon after the injury. It is often the case that
patients cannot have a full range of motion because of the nature of the injury.
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For example, fractures to the elbow and humerus cause a decrease in ROM, even
after open reduction and internal fixation. This loss in ROM is caused by the presence of
heterotopic bone, which blocks the joint from full movement. The bone develops in the
muscle proximal to the site of injury. Excision of the heterotopic bone can significantly
help patients with ROM, but physical therapy must be completed soon after the surgery
and for a number of months. Although surgery will help, HO is likely to develop again,
but with a smaller amount of bone present.
Normally, an x-ray will confirm the presence of heterotopic bone. In most
traumatic injuries, it will take at least two weeks for it to be visible on an x-ray, but as
time goes on, the heterotopic bone will continue to grow. Orthopedic surgeons, along
with the help of radiologists, are able to monitor its activity and determine when action
should be done to correct it. Furthermore, it is common for a CT (computed tomography)
scan to be done in order to get a three dimensional view of the developing bone. This is
especially important when HO develops in multiple locations where there are pieces of
bone rather than the formation of one large fragment.
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Figure 2: The presence of heterotopic bone effectively blocks extension of the triceps.
Because the heterotopic bone lies in the muscle plane, the triceps are not able to extend
fully, leading to a loss in ROM. The heterotopic bone can be seen developing behind the
elbow, proximal to the site of injury.

Because heterotopic bone can cause a loss in ROM in the elbow, patients can
have severe limitations for normal activities such as being able to straighten the arm fully
(extension) and flex the arm to bring it closer to the face. In severe cases, the joint may
not be able to extend or flex at all, meaning that the patient will require surgery to remove
the heterotopic bone to make use of the joint again.
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While HO affects joints and movement, it also has an impact on the rest of the
human body. If a patient is severely limited from using one of their knees or elbows, the
other joint will have to compensate for the loss in movement. For example, elderly
patients that undergo surgery to the elbow still tend to use the injured joint less often,
even after physical therapy. When patients need to get up from a sitting position, they
often use their arms to assist them. Because the elbow is injured and there may be a
significant loss in ROM, the non-injured elbow must bear the patient’s weight that
normally would have been split between the two arms. Perhaps this imbalance in
movement could cause damage to the glenohumeral joint (shoulder joint) over time. This
damage would likely accelerate the need for a shoulder replacement.
The example of the elbow injury is not necessarily unique, as the development of
bone near the spinal cord would affect walking movement. Any type of heterotopic bone
that develops near a joint, or that could affect movement, will limit the ability of patients
to have a functional use of their bodies. In the severe genetic diseases, it is only a matter
of time before immobilization occurs.
Treatment
Different types of treatment are available to patients, including the taking of drugs
(Indomethacin), prophylactic radiation, excision of heterotopic bone, and external beam
radiation. Statistical data showing the effects of these various types of treatment will be
examined, as many case studies have been performed in the past. Numerous ideas are
available for future treatment by physicians and researchers, which may prove to be
invaluable for the elimination of heterotopic bone.
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There are many types of treatment available to physicians to treat heterotopic
ossification, and experimental studies are underway to come up with more ways to treat
it. Perhaps the most common form of treatment is the administration of various drugs,
such as Didronel, which is a bisphosphonate that prevents calcium from being deposited
in the bony matrix that HO has already formed. Didronel is an inhibitor of the conversion
of amorphous calcium phosphate to hydroxyapatite crystals (Evans, 1991). This treatment
seeks to prevent mineralization of the bone matrix. It is only a preventative drug and it
will not have an effect on existing ossification. Therefore, it is routinely administered
before surgery that may induce HO. However, in the case of traumatic injuries, it may not
be able to prevent the ossification that begins once the injury occurs. Another drug,
Indomethacin, is a prostaglandin synthase inhibitor, serving as an anti-inflammatory drug
that suppresses mesenchymal cells, preventing further bone growth.
Radiation therapy has been used on HO since the end of the twentieth century,
and is typically performed within a few days after the excision of the heterotopic bone.
Following surgery, patients may have an active range of motion, but must go through
intense physical therapy multiple times per week in order to prevent the joint from
stiffening. In addition to physical therapy, home exercises must be completed to keep the
joint as active as possible. This helps to decrease the chance of loss of ROM due to the
development of scar tissue and the onset of ankylosis, which is commonly linked to joint
stiffness.
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Treatment Options
Non-steroidal anti-inflammatory drugs (NSAIDs). Today, the most popular
treatment for heterotopic ossification is the use of non-steroidal anti-inflammatory drugs
(NSAIDs). NSAIDs are known to have anti-inflammatory effects and are generally taken
before and/or after excision of heterotopic bone. Most doctors agree that the drug
Indomethacin is the best choice among NSAIDs to not only prevent HO, but also to slow
down the process of development. The drug works by preventing inflammation,
inhibiting bone remodeling by prostaglandins, and by inhibiting osteoprogenitor cells
(precursor to osteoblasts) from differentiating (Vanden Bossche & Vanderstraeten, 2005).
In a study conducted by Banovac, thirty-three patients classified as either
paraplegic or tetraplegic following a spinal cord injury participated in a double-blind,
randomized, placebo-controlled clinical trial. Patients were divided into two groups,
receiving either the drug Indomethacin (dose of 75 mg/day) or a placebo for a total of
three weeks (Banovac, Williams, Patrick, & Haniff, 2001). Only males participated in the
study, as men are more prone to developing HO, and also the size of the heterotopic bone
is much larger than those in women. Bone scintigraphy was used to allow early bone
detection, demonstrating a significant difference between the two groups. The group
receiving the NSAIDs showed both a decrease in early bone development and a
retardation of inflammation, including swelling, fever, and redness. In contrast, late bone
development was present in only 12.5% of those taking Indomethacin compared to 41%
of the other group that were given the placebo (Vanden Bossche & Vanderstraeten,
2005). Thus, the use of anti-inflammatory drugs can help prevent the development of
heterotopic bone and slow the growth process occurring from traumatic injuries.
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Different NSAIDs such as methylprednisolone, verapamil, warfarin, and calcitonin have
been tested against the effectiveness of Indomethacin, but there has been no observed
benefit to using alternative NSAIDs (Van Kuijk, 2002).
Radiation treatment. For heterotopic ossification, radiation treatment is often
seen as a supplement to the use of NSAID’s, but not as a complete substitute. Radiation
treatment is used because it helps to prevent the differentiation of mesenchymal cells into
osteoblasts. Therefore, it is useful to use radiation both pre- and postoperatively for bone
fractures and operative treatment, such as a total hip replacement.
Although studies have shown radiation therapy to slow the development of HO,
there is concern that it may cause carcinogenesis. However, there is also reasonable doubt
among physicians concerning carcinogenesis because of the low dose of radiation used.
Most of the patients that undergo radiation therapy are elderly, and the onset of
malignancy does not begin until fifteen years after radiation. It is difficult to predict
malignancy since most patients do not live long enough for the effects to be observed
(Baird & Kang, 2009). If radiation therapy were to be used to prevent HO from a bone
fracture in a young person, it would be worth researching in the future to ensure that any
treatments are not harmful to the patient.
Combination therapy. An increasingly popular treatment for heterotopic
ossification is the use of combination therapy, which combines the effectiveness of both
radiation treatment and the use of NSAIDs. In a study by Pakos, it was demonstrated that
only 1 out of 54 patients had clinically significant HO when using combination therapy.
There was an overall incidence rate of 20.4%, but most patients were not affected by the
development of HO (Pakos et al., 2006). Although this rate is higher than those seen in
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other similar studies, it shows that combination therapy may be able to play a significant
role in the future. Because there were fewer patients affected by the HO, it could be
useful for keeping the ossification irrelevant rather than preventing it altogether.
Researchers agree that more trials involving a larger number of patients should be
implemented to test the utility or lack thereof of combination therapy treatments.
Surgical excision. In order to prevent the reoccurrence of HO, surgical excision
of the heterotopic bone is completed after the bone is able to reach radiological
maturation and there is no significant activity involving bone development. The average
wait time for surgery is about 18 to 24 months, allowing the bone to become stable and
discourage regrowth (Garland, 1991). Because patients must wait a long time for surgery,
there is a significant loss in physical independence, an increase in soft-tissue contractures,
and a decrease in muscle functionality (Tsionos, Leclercq, & Rochet, 2004). The lack of
muscle mobility during the waiting period may not bode well for patients, even after
surgical excision is complete.
There is must debate as to the appropriate time to remove heterotopic bone, but
doctors strive to complete it in a way that not only helps patients regain their mobility,
but also to prevent HO from developing in the future. Although the chance of
reoccurrence is high, the amount of bone present following surgical excision will be
significantly smaller than the HO present after the initial injury.
Future Treatment
As the popularity for the use of NSAIDs and radiation therapy has gone up, so
have the prospects for new treatment options. Indomethacin, although effective for
treating HO, has resulted in the development of gastric ulcers and gastrointestinal
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hemorrhages in some patients (Karunakar et al., 2006). In addition, radiation therapy has
its drawbacks, including carcinogenesis, gonadal dysfunction, and bony nonunion
(Balboni, Gobezie, & Mamon, 2006). Many of these side effects have a larger impact on
patients rather than the HO itself, so there is also no consensus at to what the best options
are today. Thus, new studies are underway to discover treatments that have an increased
efficacy and fewer side effects (Baird & Kang, 2009). The following section will address
treatment options that researchers hope will be more effective for patients with
heterotopic ossification.
Noggin. As discussed previously, HO is thought to develop due to overexpression
of BMPs (bone morphogenetic proteins). Along with the upregulation of BMPs, the
downregulation of BMP antagonists could provide an environment suitable for the
development of heterotopic bone. Noggin, a BMP antagonist, is an extracellular protein
that binds to BMPs and causes inactivation (Baird & Kang, 2009). A study by Hannallah
showed that when Noggin was delivered to tissue following trauma, there was an 83%
decrease in area of HO (Hannallah et al., 2004). Other studies have shown that the direct
delivery of Noggin using an adenovirus vector blocks BMP-4-induced heterotopic
ossification (Glaser et al., 2003).
Today, research is focused on systemic delivery of Noggin in order to prevent
heterotopic ossification in animal models. Although it has been tested on animals, it may
not be safe for human use. The overall goal of Noggin treatment is to be able to use the
antagonistic nature of the protein to suppress BMPs, and help patients with fractures. It is
unknown whether this type of treatment can be used before surgeries such as a hip
arthroplasty as a preventative measure, or if it can only affect the activity of BMPs
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following an injury or surgery.
Pulsed electromagnetic fields (PEMF). Research is now being directed to the
area of pulsed electromagnetic fields (PEMF) to prevent heterotopic ossification
following traumatic injuries and surgeries. PEMF is of interest due to its ability to
increase circulation and oxygenation rates in soft tissue. HO is suspected to occur, in part,
because of a local hypoxia, or lack of oxygen to areas that have been affected by injuries.
Studies with PEMF have shown that early treatment can help prevent the development of
HO following total hip arthroplasty, especially in severe cases (Kocic et al., 2006). There
have not been enough studies to make an appropriate prophylaxis, but PEMF is being
tested on humans rather than animals, which may give more conclusive results. The
positive outcomes of recent studies show that it may help patients, but the side effects of
using electromagnetic fields on the body could be dangerous.
Free radical scavengers. In the human body, there is oxidative stress when the
reactive oxygen species (free radicals) are produced at a faster rate than their rate of
elimination (Vanden Bossche & Vanderstraete, 2005). Treatment making use of free
radical scavengers includes exercise that assists with reperfusion of soft tissue, or the
bringing of blood flow to the tissue of interest. When blood is able to flow to an area that
has been deprived of oxygen, it allows the cells to replenish their supply of nutrients
necessary for functionality. Free radical generation occurs as a result of the exercise
treatments, allowing the rate of elimination to come close to the rate of production. With
heterotopic ossification, muscle atrophy occurs as a result of the decrease in protein
synthesis, which weakens the repair mechanisms of cells. To disturb the environment
suitable for HO, free radicals may be used in the future as a preventative measure.
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Allopurinol and N-acetylcysteine were used as free radical scavengers in an animal
experiment that tested the development of HO. The study concluded that the reactive
oxygen species were as effective as NSAID’s in preventing heterotopic bone formation
(Vanden Bossche & Vanderstraete, 2005). Again, additional studies will be needed to
allow treatment on humans and the potential side effects remain unknown.
Overall, it is the hope of researchers that these new treatments will be investigated
further and made available for regular use. With these new techniques, there may be
reduced complications with HO following surgery or trauma, along with fewer side
effects. For now, the use of NSAIDs, radiation treatment, and combinations of the two
seem to reduce the incidence of HO effectively. However, there may be better options for
patients in the future, so it is only a matter of time before the best alternative arises from
continued research.
Conclusion
Heterotopic ossification is known as the process by which bone develops in soft
tissue where it does not normally reside. Because of its presence, it has many effects on
patients including loss of range of motion, swelling, pain, joint immobility, and bone
deformation. Over time, many of these symptoms seem to adversely affect the lifestyle of
patients, ranging from slight discomfort to complete immobility. There are many ways
that heterotopic ossification is able to develop, whether it is from genetics, surgery,
injury, or burns. For every genetic case, there are symptoms to help identify the disorder,
but there are not many options available for treatment. The degree of immobility is higher
among those who inherit the disease genetically, which usually comes with a shortened
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life expectancy. For those that develop HO as a result of a surgery or injury, there are
many treatment options available.
The most popular forms of treatment are radiation therapy and non-steroidal antiinflammatory drugs. While they may be effective at suppressing the development of
heterotopic bone, there is no physiological solution to completely eliminating HO. For
every treatment available, there are reasons to be wary of its use. Therefore, new
treatment options for patients are being researched in hopes of reducing the number of
side effects and being more effective at eliminating HO. Future treatment may include
Noggin, PEMF, and free radical scavengers.
The complete genetic basis for heterotopic ossification remains unknown to
researchers, although certain types such as FOP have been linked to BMP’s. Mutations in
the human genome will lead to a genetically-based form of HO, while stress to the body
resulting from injury or surgery will lead to an obtained form. It is believed that all types
of HO can be linked to the activity of mesenchymal cells, the precursor to osteoblasts,
which build bone. Research is being done to inhibit the activity of the BMP signaling
pathway and prevent unnecessary bone growth.
While heterotopic ossification remains a medical mystery, there is much to be
researched in order to treat patients effectively. The disorder is relatively unknown, but it
complicates the lives of those who have it. In the future, scientists hope to have a better
understanding of HO and what causes it to occur. For now, patients have limited
resources and may never be able to have a full physical healing. The prospects for
enhanced treatment look promising, and it is only a matter of time before scientists, along
with the help of technology, discover the cure to heterotopic ossification.
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